Drug Discovery, the Development of Toxicogenomics and Pharmacogenomics, Translational Medicine | GenomeWeb

In 2005 — with scientists still trying to suss out the impact genomics could have on various fields of research — Genome Technology's July/August issue delved into the impact of toxicogenomics, pharmacogenomics, and RNAi on drug development. Genomics seemed to offer a gentler option to traditional toxicology, which GT called "pretty brutal." At that time, the value of genomics in drug development was still being debated, and though researchers could theoretically see the potential benefits of the various genomic applications, they weren't being widely used.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.